Our notes on Thursday highlighted the 2012 potential of Accentia Biopharmaceuticals (ABPI) and its majority-owned subsidiary Biovest International (BVTI) based on the progression of BVTI's late stage immunotherapeutic treatment for non-Hodgkin's lymphoma, BiovaxID. Non-Hodgkin's lymphoma is an incurable form of blood cancer and it's expected that Biovest will officially file for approval with the FDA later this year.
Another press release hit the wires on Thursday from these two companies that brings another angle to the table. According to the PR, Biovest "has entered into a key Research Agreement with the Max Planck Institute for Dynamics of Complex Technical Systems. Max Planck Institute will conduct a series of influenza virus growth studies designed to establish the advantages of Biovest’s proprietary Hollow Fiber Bioreactor Systems for the efficient and cost-effective cell culture manufacture of viral vaccines."
Financial terms of the deal were not disclosed, but this research follows earlier research conducted by Biovest and and the Naval Health Research Center (NHRC), a collaboration which produced encouraging results and have already been published for public consumption in Genetic Engineering & Biotechnology News (GEN).
As the plan for a BiovaxID approval takes shape, Biovest holds even further potential in the technology behind its science.
Biovest CEO, Sam Duffey, stated in the release that, "As the potential for new viral threats are forecast to emerge, there has never been greater demand for a highly efficient vaccine production platform that can be rapidly scaled to meet the need and, when necessary, rapidly deployed to needed locations. Based on the encouraging data reported by the NHRC and our collaboration with the Max Planck Institute, we believe Biovest’s Hollow Fiber Systems are becoming well-positioned as a scalable, portable and highly-efficient manufacturing platform that can help meet this urgent need.”
Already benefiting from additional attention on the cancer immunotherapy sector in early 2012, Biovest may be setting itself up for a pivotal year as its technology and products further develop.
Disclosure: No positions. May purchase shares of BVTI and/or ABPI within the next 72 hours.